INTRODUCTION {#s1}
============

Gastric cancer is the fourth most common cancer worldwide, the third leading cause of cancer-related death in males and the fifth among females \[[@R1]\]. Although the incidence and mortality of gastric cancer have declined, it is still one of the most significant health burdens in the world \[[@R1], [@R2]\]. Treatment with chemotherapy has limited effects and usually serves as palliative care to relieve patient symptoms and increase survival time \[[@R1]\]. To date, surgical resection remains the only curative means to improve survival. As the underlying mechanisms responsible for the development and progression of gastric cancer are still poorly understood, further investigation is needed to develop novel preventative strategies. However, it is known that *Helicobacter pylori* infection induces chronic non-atrophic gastritis which can progress to intestinal metaplasia, dysplasia and finally gastric cancer \[[@R3]\]. Epidemiologic, animal and clinical studies have confirmed this critical role of *H. pylori*, which has been classified as a class I carcinogen for gastric cancer by the International Agency for Research of Cancer \[[@R4]\].

*H. pylori* infection is known to disturb the functions of some tumor suppressor genes and oncogenes in gastric tissue \[[@R5]-[@R10]\], which may be the initial carcinogenic trigger. Phosphatase and tensin homolog (*PTEN*), a tumor suppressor gene identified in 1997 \[[@R11]-[@R13]\], encodes a lipid and protein phosphatase that is involved in the regulation of a variety of signaling transduction pathways, including the PI3K/Akt pathway, which are critical in cell apoptosis, adhesion and mobility, as well as in the regulation of chromosomal stability \[[@R14]-[@R18]\]. PTEN is frequently inactivated in various human cancers \[[@R11], [@R12], [@R19]-[@R21]\], and several studies have indicated that PTEN is frequently inactivated in gastric cancers due to genetic or epigenetic changes, such as mutation, loss of heterozygosity, promoter hypermethylation and regulation of microRNA \[[@R22]-[@R26]\]. However, it remains to be defined whether other mechanisms account for inactivation of PTEN and how PTEN inactivation promotes carcinogenesis.

PTEN activity can be regulated by a variety of mechanisms, including acetylation, oxidation, ubiquitination, and most importantly, by phosphorylation \[[@R27]-[@R32]\]. Several phosphorylation sites have been identified in PTEN that lead to a loss of phosphatase activity or a gain of stability, such as Ser380, Thr382, and Thr383 \[[@R27], [@R28]\], which ultimately may result in loss of tumor suppressor function and increased cancer susceptibility. An increase in phosphorylation of this C-terminal serine-threonine cluster and PTEN inactivation is observed in T-cell acute lymphoblastic leukemia and adult T-cell leukemia-lymphoma \[[@R33], [@R34]\]. In a previous study, we demonstrated that aberrant phosphorylation of PTEN at residue Ser380 was an early event that could contribute to gastric carcinogenesis \[[@R21]\]. Therefore, the aim of the present study was to determine the expression and phosphorylation of PTEN at residues Ser380/Thr382/383 in gastric lesions of different stages with or without *H. pylori* infection. Furthermore, the effect of *H. pylori* infection on PTEN phosphorylation and activation of downstream PI3K/Akt pathway-related proteins was evaluated *in vitro* and *in vivo* in an effort to identify mechanisms of gastric carcinogenesis.

RESULTS {#s2}
=======

PTEN phosphorylation is increased in gastric cancer tissues {#s2_1}
-----------------------------------------------------------

Western blotting was performed on protein samples from gastric cancer tissues to determine if PTEN is phosphorylated at residues Ser380/Thr382/383. A reduction in PTEN expression was detected in 13 of the 15 (86.7%) primary gastric cancer samples (in a range of 0.07--1.46, mean = 0.59, p \< 0.001), though ten cases (66.7%) showed an increase in the proportion of phosphorylated PTEN in gastric cancer tissues compared with the paired adjacent mucosa (in a range of 0.48--2.26, mean = 1.29, p \< 0.05) (Figure [1](#F1){ref-type="fig"}).

![Phosphatase and tensin homolog is phosphorylated in gastric cancer tissues\
Immunoblots of phosphatase and tensin homolog (PTEN), phosphorylated (p)-PTEN and β-actin were used to quantify the relative protein expression levels in patient samples; densitometric units of gastric tumor samples (T) are expressed as fold of their non-cancerous counterparts (N). The samples derive from the same experiment and that blots were processed in parallel. \**p* \< 0.05; \*\*\**p* \< 0.001.](oncotarget-06-31916-g001){#F1}

Phosphorylated PTEN in chronic non-atrophic gastritis is enhanced with *H. pylori* infection {#s2_2}
--------------------------------------------------------------------------------------------

Immunohistochemistry was performed to evaluate the phosphorylation of PTEN throughout the various stages of gastric carcinogenesis. The results show that weak to strong expression of PTEN was observed in 92.5%, 65.0%, 70.0%, and 37.5% of chronic non-atrophic gastritis, intestinal metaplasia, dysplasia, and gastric cancer, respectively. PTEN expression level was significantly decreased in gastric cancer compared to chronic non-atrophic gastritis, intestinal metaplasia, or dysplasia (*ps* \< 0.05) (Figure [2A](#F2){ref-type="fig"}). In addition, there was significant difference in PTEN expression between the tissue specimens of chronic non-atrophic gastritis and intestinal metaplasia (*p* \< 0.01) (Figure [2A](#F2){ref-type="fig"}). Moreover, Weak to strong phosphorylated PTEN was observed in 57.5%, 87.5%, 82.5%, and 75.0% of chronic non-atrophic gastritis, intestinal metaplasia, dysplasia, and gastric cancer, respectively, indicating that phosphorylated PTEN was significantly increased in intestinal metaplasia, and dysplasia compared to chronic non-atrophic gastritis (*ps* \< 0.001) (Figure [2A](#F2){ref-type="fig"}). Again, there was significant difference in phosphorylated PTEN between intestinal metaplasia or dysplasia and gastric cancer (*ps* \< 0.05) (Figure [2A](#F2){ref-type="fig"}). Nevertheless, our data obtained from 25 cases of gastric cancer do not show an obvious association between PTEN or phosphorylated PTEN levels and clinicopathological grades ([Table S1](#SD1){ref-type="supplementary-material"}). These data suggest that phosphorylation of PTEN is an early event and may contribute to gastric carcinogenesis.

![Phosphorylation of phosphatase and tensin homolog throughout the development of gastric cancer and in relation to *H. pylori* infection\
Gastric tissue samples were stained with antibodies against phosphatase and tensin homolog (PTEN) and phosphorylated (p)-PTEN; immunoreactive cells positive for PTEN and p-PTEN were semi-quantitatively assessed, and the protein expression levels are expressed as grade 1--4 in A: all patients in various stages of gastric lesions and B: patients in various stages of gastric lesions with or without *H. pylori* infection. Mean grades (−) for protein expression are shown. CNAG, chronic non-atrophic gastritis; IM, intestinal metaplasia; Dys, dysplasia; GC, gastric cancer. Scale bar = 40 μm. \**p* \< 0.05; \*\*\**p* \< 0.001.](oncotarget-06-31916-g002){#F2}

As it has been postulated that *H. pylori* infection may trigger gastric carcinogenesis, the same cohort of patients were divided to *H. pylori*-positive and -negative two groups, and the phosphorylation of PTEN was examined in patients with or without *H. pylori* infection. Immunohistochemical analysis revealed that infection with *H. pylori* did not affect the loss of PTEN expression, however, the phosphorylated PTEN was significantly increased by infection in chronic non-atrophic gastritis (*p* \< 0.05) (Figure [2B](#F2){ref-type="fig"}). These results suggest that *H. pylori* infection enhances or accelerates the phosphorylation of PTEN.

*H. pylori* infection induces phosphorylation of PTEN and activation of the PI3K/Akt pathway in gastric tissue from Mongolian gerbils {#s2_3}
-------------------------------------------------------------------------------------------------------------------------------------

The Mongolian gerbils were successfully infected with *H. pylori* which was confirmed by Giemsa staining, no animals challenged with Brucella broth alone had detectable evidence of *H. pylori*.

To confirm that *H. pylori* infection induces phosphorylation of PTEN and assess downstream activation *in vivo*, immunohistochemical analysis of PTEN and PI3K/Akt pathway-related proteins (*i.e.*, Akt, phosphorylated Akt \[active phosphorylation of Akt\], Bad, and phosphorylated Bad \[inhibitory phosphorylation of Bad\]) was performed from gastric tissue samples of Mongolian gerbils with or without *H. pylori* infection after 6 and 12 months. Although the expression levels of PTEN, Akt, and Bad did not differ, the levels of phosphorylated PTEN, phosphorylated Akt, and phosphorylated Bad were higher 6 and/or 12 months after *H. pylori* infection (*ps* \< 0.05) (Figure [3](#F3){ref-type="fig"}). Interestingly, the levels of phosphorylated PTEN and all downstream PI3K/Akt pathway-related proteins was higher in Mongolian gerbils sacrificed at 12 months than those sacrificed at 6 months regardless of *H. pylori* infection, suggesting pathway activation with age.

![*H. pylori* infection induces phosphorylation of phosphatase and tensin homolog and PI3K/Akt pathway-related proteins in gastric tissue of Mongolian gerbils\
Gastric tissue sections from *H. pylori-*infected gerbils were taken after 6 or 12 months and stained for antibodies against A: phosphatase and tensin homolog (PTEN) and phosphorylated (p)-PTEN and B: Akt, p-Akt, Bad and p-Bad. Immunoreactive cells were semi-quantitatively assessed, and the protein expression levels are expressed as grade 1--4. Mean grades (−) for protein expression are shown. Scale bar = 40 μm. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001.](oncotarget-06-31916-g003){#F3}

*H. pylori* induces phosphorylation of PTEN and activation of the PI3K/Akt pathway *in vitro* {#s2_4}
---------------------------------------------------------------------------------------------

Incubation of non-malignant GES-1 cells with *H. pylori* resulted in a significant increase in the proportion of phosphorylated PTEN as compared with a control (*ps* \< 0.01) (Figure [4A](#F4){ref-type="fig"}). In addition, the proportions of phosphorylated Akt (Ser473 and Thr308) and Bad were increased with *H. pylori* incubation (*ps* \< 0.05) (Figure [4B](#F4){ref-type="fig"}). The increased phosphorylation of these proteins demonstrated a dose dependency (at 1h) ([Figure S1](#SD1){ref-type="supplementary-material"}), suggesting that *H. pylori* also induces phosphorylation of PTEN and activation the PI3K/Akt pathway *in vitro*.

![*H. pylori* induces phosphorylation of phosphatase and tensin homolog and PI3K/Akt pathway-related proteins *in vitro*\
Cultures of gastric epithelial cells (GES-1) were incubated for various times with *H. pylori* (multiplicity of infection \[MOI\] = 50) in *H. pylori* group or with medium in control group. Immunoblots of A: phosphatase and tensin homolog (PTEN) and phosphorylated (p)-PTEN and B: Akt, p-Akt, Bad, p-Bad and β-actin were used to quantify the relative protein expression levels (expressed as fold of control). The data are representative of three independent experiments. The samples derive from the same experiment and that blots were processed in parallel. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001.](oncotarget-06-31916-g004){#F4}

Activation of the PI3K/Akt pathway by PTEN regulation {#s2_5}
-----------------------------------------------------

To determine the role of PTEN regulation on *H. pylori*--induced activation of the PI3K/Akt pathway, stable cell lines expressing a wild-type or dominant-negative mutant PTEN (C124S) were tested. PTEN was overexpressed in stable cell line carried with the wild-type PTEN which display its phosphatase activity soundly. However, a dominant-negative mutant PTEN of C124S was the catalytically dead mutant form of the phosphatase. Phosphorylation and inactivation of PTEN at residues Ser380/Thr382/383 were mimiced in stable cell line carried with a dominant-negative mutant PTEN. Further, the empty vector was not carried with any exogenous gene. As expected, *H. pylori* (multiplicity of infection \[MOI\] = 50 for 1h) resulted in significant increases in the phosphorylation of PTEN, Akt, and Bad in the stable cell line expressing the wild-type PTEN, similar to that observed in GES-1 cells and a stable cell line expressing an empty vector (all *ps* \< 0.05) (Figure [5](#F5){ref-type="fig"}). However, there was an increase in the proportion of phosphorylated PTEN with *H. pylori*, but no difference in the phosphorylation of Akt or Bad in the stable cell line expressing the mutant PTEN. These data suggest that a mutant inactive PTEN mimics *H. pylori*-induced activation of the PI3K/Akt pathway.

![*H. pylori*-induced phosphorylation P13K/Akt pathway-related proteins is blocked in cells expressing mutant phosphatase and tensin homolog\
Immunoblots of phosphatase and tensin homolog (PTEN), phosphorylated (p)-PTEN, Akt, p-Akt, Bad, p-Bad and β-actin from gastric epithelial cells (GES-1) stably expressing an empty vector (Empty), wild-type (WT) or mutant dominant-negative phosphatase and tensin homolog (C124S) (MT) were used to quantify the relative protein expression levels after a 1 h incubation with *H. pylori* (multiplicity of infection = 50) (expressed as fold of control). The data are representative of three independent experiments. The samples derive from the same experiment and that blots were processed in parallel. \**p* \< 0.05; \*\**p* \< 0.01.](oncotarget-06-31916-g005){#F5}

However, *H. pylori* has been reported to activate PI3K directly \[[@R35]-[@R40]\]. In present study, inhibition of PI3K with LY294002 did not affect phosphorylation of PTEN, but diminish phosphorylation of Akt or Bad upon incubation with *H. pylori* (MOI = 50 for 1h) or not ([Figure S2](#SD1){ref-type="supplementary-material"}). In addition, Akt Inhibitor VIII blocked the *H. pylori*-induced phosphorylation of Akt and Bad, but not PTEN (MOI = 50 for 1h) ([Figure S3](#SD1){ref-type="supplementary-material"}). Therefore, these results suggested that the mechanisms of activation of Akt by *H. pylori* involve direct activation of PI3K and phosphorylation and inactivation of PTEN.

*H. pylori* promotes gastric epithelial cell viability through the PTEN/Akt pathway {#s2_6}
-----------------------------------------------------------------------------------

Aberrant activation of the Akt pathway induced by *H. pylori* infection may affect cell viability. Evaluation of cell viability using an MTT assay showed that *H. pylori* increased the growth rate of GES-1 cells in both a time- and dose-dependent manner (Figure [6A](#F6){ref-type="fig"}), and the proliferation rates were also increased as determined by a BrdU assay (Figure [6D](#F6){ref-type="fig"}); However, apoptosis rates were not affected as determined by flow cytometry analysis (MOI = 50) (Figure [6E](#F6){ref-type="fig"}). The *H. pylori*-induced increased growth was blocked by mutant PTEN C124S expression (Figure [6B](#F6){ref-type="fig"}) and Akt inhibition (Figure [6C](#F6){ref-type="fig"}). A similar effect was observed *in vivo*, as *H. pylori* infection increased cell proliferation in gastric tissue after 6 months as determined by proliferation cell nuclear antigen (PCNA) immunostaining ([Figure S4](#SD1){ref-type="supplementary-material"}). This difference was not apparent after 12 months of infection, likely masked by the increased proliferation observed in both groups at 12 months compared to 6 months. The increased proliferation was not a result of decreased apoptosis, as there was no difference among the groups as determined by a TUNEL assay. Taken together, these results strongly suggest that phosphorylation and inactivation of PTEN induced by *H. pylori* promotes gastric epithelial cell survival through the Akt pathway.

![*H. pylori* promotes gastric epithelial cell survival through phosphorylation of phosphatase and tensin homolog and activation of Akt pathway\
Cell survival was assessed using a modified MTT assay, and the cell survival rate was expressed as percentage of control or gastric epithelial cells (GES-1) at different time points after A: incubation with various doses (multiplicity of infection \[MOI\]) of *H. pylori*, B: in cells stably expressing an empty vector (Empty, wild-type (WT) or mutant dominant-negative phosphatase and tensin homolog (C124S) (MT), or C: after incubation with an inhibitor of Akt. D: Proliferation in control or *H. pylori-*infected cells was assessed using a BrdU assay, and the proliferation rate was calculated as the percentage of control or *H. pylori-*infected cells at 0 h. E: Apoptosis in control or *H. pylori-*infected cells was assessed using a flow cytometry analysis, and the apoptosis rate was calculated as the ratio of "Q2 + Q3" to the total cell number. The data are representative of three independent experiments. \**p* \< 0.05; \*\*\**p* \< 0.001.](oncotarget-06-31916-g006){#F6}

DISCUSSION {#s3}
==========

Although it has been suggested that PTEN is vital to gastric carcinogenesis, data supporting this conjecture remain mostly limited to associations with genetic or epigenetic changes \[[@R22]-[@R26]\]. However, PTEN inactivation through increased phosphorylation of its C-terminal serine-threonine cluster is observed in some hematopoietic tumors \[[@R33], [@R34]\]. In a previous study, we demonstrated that aberrant phosphorylation of PTEN at residue Ser380 is an early event that could contribute to gastric carcinogenesis \[[@R21]\]. The results of the present study show that PTEN phosphorylation at Ser380/Thr382/383 is abnormally increased in gastric cancer tissues.

The development of gastric cancer is considered a multistep process beginning with chronic non-atrophic gastritis, and progressing through intestinal metaplasia and dysplasia to gastric cancer \[[@R3]\]. The data show that this progression is paralleled by a loss of PTEN, and taking into account total PTEN reduction, an increase in phosphorylated PTEN, yielding a sustained high expression in intestinal metaplasia, dysplasia and gastric cancer. Additionally, the results revealed that the phosphorylated PTEN was significantly higher in patients with chronic non-atrophic gastritis that were infected with *H. pylori*, but not at later stages of gastric carcinogenesis. Although *H. pylori* is a class I carcinogen for gastric cancer \[[@R4]\], it is one of risk factors for gastric cancer and is often combined with other factors, such as genetics, the environment, diet, and socio-economic status to jointly lead to gastric cancer. Taking into account the result that phosphorylated PTEN is progressively increased in gastric carcinogenesis regardless of *H. pylori* infection, we speculate that not only *H. pylori* infection, but also other risk factors may induce phosphorylation of PTEN in gastric carcinogenesis, however, *H. pylori* infection could accelerate the phosphorylation of PTEN in the early stages of gastric carcinogenesis. And further studies incorporating different risk factors are needed. In addition, the effect of *H. pylori* on PTEN phosphorylation was further demonstrated both *in vivo* and *in vitro*. These results further support the role of PTEN phosphorylation in gastric carcinogenesis, and suggest that *H. pylori* infection accelerates this process.

The PI3K/Akt pathway is downstream of PTEN \[[@R14]\] and is frequently activated in gastric carcinogenesis and vital to gastric cancer development \[[@R41]\]. This pathway was found to be activated by *H. pylori* infection both *in vivo* and *in vitro*, which is consistent with previous studies \[[@R9], [@R10], [@R35]-[@R40], [@R42]\]. Interference with PTEN activity with a dominant-negative mutant inhibits the effect of *H. pylori* on the Akt pathway, and suppressing Akt blocked the increase in cell survival, which suggest that the mechanisms of activation of Akt by *H. pylori* involve direct activation of PI3K and phosphorylation and inactivation of PTEN. Aberrant PI3K/Akt pathway signaling is the underlying defect found in several pathologies. Akt is one of the most frequently activated kinases in human cancer and can promote unregulated cell proliferation. Based on the data observed in the present study, we conclude that *H. pylori* infection leads to phosphorylation of PTEN at residues Ser380/Thr382/383 and aberrant activation of the PI3K/Akt pathway, resulting in increased cell survival both *in vivo* and *in vitro*, which is consistent with previous work \[[@R5], [@R36]\].

Although these results enhance our understanding of gastric carcinogenesis with relation to *H. pylori* infection, there are a few limitations in the present study. For example, the study was based only on a CagA^+^ and VagA^+^ strain of *H. pylori*, and the virulence factors responsible for phosphorylation of PTEN at residues Ser380/Thr382/383 are still unknown. Further, the study only focused on inactivation of lipid phosphatase activity of PTEN and not regulation of other downstream factors, such as focal adhesion kinase \[[@R15], [@R17]\].

In addition, there is a discrepancy in this study. In present study, we found that *H. pylori* promotes gastric epithelial cell proliferation *in vitro*, which was different from our previous study that *H. pylori* filtrates have cytostatic and cytotoxic effects on gastric cells by inducing DNA damage, G1/S cell cycle arrest, and apoptosis \[[@R9]\]. Indeed, increased proliferation and reduced survival of *H. pylori*-infected cells have been reported previously \[[@R43]\]. These seemingly opposing results reveal the diverse effects of *H. pylori* infection that could often be reconciled by differences in experimental models \[[@R43]\]. An interesting example is a recent study by Wroblewski *et al*., who have provided evidence that the *H. pylori* strains which inhibit growth of gastric cells in a co-culture model induce cellular proliferation in gastric organoids \[[@R44]\]. Therefore, further studies incorporating different models are needed.

In conclusion, this study indicates that reduced expression of PTEN and increased PTEN phosphorylation at residues Ser380/Thr382/383 could contribute to gastric carcinogenesis, and targeting phosphorylation at these sites could be a novel mechanism for treating gastric carcinogenesis. Moreover, *H. pylori* accelerates this phosphorylation, which activates the PI3K/Akt pathway and promotes cell survival. Future clinical and experimental studies will help to elucidate the mechanism by which *H. pylori* induces PTEN phosphorylation, and how this advances gastric carcinogenesis.

MATERIALS AND METHODS {#s4}
=====================

Patients and tissue specimens {#s4_1}
-----------------------------

Gastric adenocarcinoma and corresponding non-cancerous tissue samples were collected during surgery from 15 patients who were not receiving any adjuvant therapy between January 2012 and June 2012 at The First Affiliated Hospital of Nanchang University. An additional 160 gastric tissue samples were collected from patients who underwent a gastroduodenoscopy at the same hospital between January 2007 and September 2009, including 40 cases of chronic non-atrophic gastritis (20 *H. pylori*-positive, 20 negative), 40 cases of intestinal metaplasia (20 *H. pylori*-positive, 20 negative), 40 cases of dysplasia (20 *H. pylori*-positive, 20 negative), and 40 gastric cancers (20 *H. pylori*-positive, 20 negative). There were no significant differences in the age or gender distribution among these groups, which are summarized in [Table S2](#SD1){ref-type="supplementary-material"}. Pathologic diagnosis and classification were made according to the criteria of the World Health Organization \[[@R45]\] and the updated Sydney system \[[@R46]\]. Detection of *H. pylori* infection was carried out using a rapid urease test and Giemsa staining as previously described \[[@R5]-[@R9]\]. Informed consent was obtained from all patients, all procedures were approved and carried out in accordance with the guidelines by the Ethics Committee of The First Affiliated Hospital of Nanchang University.

Cell line and *H. pylori* strain {#s4_2}
--------------------------------

The immortalized human gastric epithelial mucosa cell line GES-1 was cultured in Dulbecco\'s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U penicillin, and 100 μg/ml streptomycin (Gibco of Thermo Fisher Scientific Inc., Waltham, MA, USA) at 37°C in an atmosphere of 5% CO~2~. The CagA^+^ and VagA^+^ *H. pylori* type strain ATCC43504 was cultured on Campylobacter agar plates containing 10% sheep serum and incubated at 37°C under microaerophilic conditions (5% O~2~, 10% CO~2~, and 85% N~2~) for 24 h, then subcultured in Brucella broth supplemented with 10% FBS at 37°C under microaerophilic atmosphere for 16-18 h. Bacterial density was estimated spectrophotometrically as absorbance at 600 nm (OD~600~), and viable counts were determined as colony-forming units (CFU)⁄ml (1 OD~600~ = 10^9^ CFU/ml).

Mongolian gerbils {#s4_3}
-----------------

Five to eight weeks old specific-pathogen-free male Mongolian gerbils (30-50 g) provided by Zhejiang Academy of Medical Sciences (Hangzhou, Zhejiang, China) were maintained in an isolated clean room with regulated temperature (20--22°C), humidity (approximately 55%), and a 12/12-h light/dark cycle, with ad libitum rodent diet and water. After one week\'s observation, gerbils were given orogastric infusions of 1ml either sterile Brucella broth (*n* = 25) or 1 × 10^8^ CFU of *H. pylori* type strain ATCC43504 (*n* = 54) once every 3 days for a total of ten infusions. Gerbils were fasted for 12 h before, and drinking water was withheld after *H. pylori* inoculation. Both food and water were then freely available to animals 4 h after inoculation. Animals were euthanized at either 6 months (*n* = 30 *H. pylori*-infected; 15 controls) or 12 months (*n* = 24 *H. pylori*-infected; 10 controls), and linear strips of gastric tissue extending from the squamocolumnar junction through the proximal duodenum were collected. All protocols were approved and carried out in accordance with the guidelines by the Ethics Committee of The First Affiliated Hospital of Nanchang University.

Reagents and lentivirus {#s4_4}
-----------------------

Pharmacological inhibition of PI3K was achieved with LY294002 (40 μM; Sigma-Aldrich, St. Louis, MO, USA), and Akt was inhibited with Akt Inhibitor VIII (10 μM; Merck KGaA, Darmstadt, Germany). Wild-type PTEN, dominant-negative mutant type PTEN (C124S), and empty lentiviral supernatants were purchased from Invitrogen (of Thermo Fisher Scientific Inc.). For lentivirus infection, GES-1 cells were grown to approximately 60% confluence and incubated with viral supernatants and hexadimethrine bromide (Sigma-Aldrich, St. Louis, MO, USA) for 6 h. Forty-eight hours later, the cells were split and cultured in selection media containing blasticidin (Sigma-Aldrich) for an additional 2 weeks. Then the stable cell lines expressing a wild-type or dominant-negative mutant PTEN were established.

Immunoblotting {#s4_5}
--------------

Western blotting was performed according to standard methods as described previously \[[@R21]\] using anti-PTEN (\#9559; 1:10000), anti-phosphorylated (p)-PTEN (Ser380/Thr382/383) (\#9554; 1:10000), anti-Akt (\#4691; 1:10000), anti-phosphorylated (p)-Akt (Ser473) (\#9271; 1:1000), anti-phosphorylated (p)-Akt (Thr308) (\#9275; 1:1000), anti-Bad (\#4366; 1:1000), anti-phosphorylated (p)-Bad (Ser136) (\#4366; 1:1000) antibodies (Cell Signaling Technology, Danvers, MA, USA), and an anti-β-actin antibody (sc-1615-R; 1:1000; Santa Cruz Biotechnology, Dallas, TX, USA).

Immunohistochemistry {#s4_6}
--------------------

Immunohistochemistry was performed on paraffin sections of human biopsy specimens or Mongolian gerbil gastric tissues using anti-PTEN (ab31392; 1:150 \[biopsy\], 1:800 \[gastric tissues\]), anti-p-PTEN (Ser380/Thr382/383) (ab47332; 1:800 \[biopsy\], 1:1000 \[gastric tissues\]), anti-Akt (ab8805; 1:400), anti-p-Akt (Ser473) (ab66138; 1:400), anti-p-Akt (Thr308) (ab38449; 1:200), anti-Bad (ab32445; 1:1000), and anti-p-Bad (Ser136) (ab28824; 1:1000) antibodies (Abcam, Cambridge, UK) following previously described methods \[[@R6]-[@R9], [@R21]\], the specificity of the staining of different antibodies was evaluated by corresponding blocking peptides, and the negative control sections were just incubated with PBS without the primary antibodies. The stained sections were chosen, reviewed, and scored from five randomly selected high power fields (40× objective lens) by two pathologists blinded to the histopathologic data. Grading discrepancies were re-reviewed and discussed to obtain a final score. Epithelial cells with yellow or brown staining in the nucleus and/or cytoplasm was defined as positive for immunoreactivity. The percentage of immunoreactive cells from 100 cells in each field were averaged from the five fields and scored as follows: 0 \< 5.0% immunoreactive; 1 = 5.1--25.0%; 2 = 25.1--50.0%; 3 = 50.1--75.0%; and 4 \> 75.0%. Moreover, the staining intensity was also semi-quantitatively assessed as 0 = no staining; 1 = weak staining; 2 = moderate staining; and 3 = strong staining. The overall protein expression level was then reported as a grade as calculated from an integral score of the "area × intensity" as follows: grade 1 = score 0--2 (negative); grade 2 = score 3--5 (weakly positive); grade 3 = score 6--8 (moderately positive); and grade 4 = score 9--12 (strongly positive).

MTT assay, BrdU and flow cytometry analysis {#s4_7}
-------------------------------------------

Cell survival or proliferation was assessed using a modified MTT assay or a BrdU cell proliferation assay kit (EMD Millipore, Billerica, MA, USA) as described previously \[[@R47]\]. Apoptosis in cell lines was determined by using a flow cytometry analysis (Annexin V: FITC Apoptosis Detection Kit I; Becton, Dickenson and Company, Franklin Lakes, NJ, USA) according to the manufacturer\'s instructions.

Statistical analysis {#s4_8}
--------------------

Data are summarized as mean ± standard deviation (SD) or percentage of control. The chi-square test was performed to evaluate differences in categorical variables, such as gender, among different defined groups. The one-way analysis of variance (ANOVA) was used to determine the differences in numerical variables, such as patients\' ages, among the groups. Kruskal-Wallis or Mann-Whitney tests were used to determine the differences in numerical variables between differently defined groups. A p value of \< 0.05 was considered as statistically significant.
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